We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Clinical and Virological Factors Influence Dengue Immunoassay

By LabMedica International staff writers
Posted on 03 Aug 2011
An evaluation has been made of the factors that influence the performance of an antigen capture assay and other markers of dengue disease severity.

Dengue nonstructural protein 1 (NS1) may be used in simple antigen-capture enzyme-linked immunosorbent assay (ELISA) for early detection of dengue virus infection.

A team from the Institute Pasteur in Phnom Penh (Cambodia) collected blood from patients hospitalized during the 2006 and 2007 dengue epidemics in Cambodia. Blood samples were tested for hematocrit and platelet count as well as for other biological parameters necessary for patients' follow-up. Sera were tested for dengue using serology and molecular methods at the Institute Pasteur in Cambodia. Dengue infection was confirmed in 243 of 339 symptomatic patients and in 17 asymptomatic individuals out of 214 household members tested.

Overall sensitivity and specificity of Platelia NS1 Ag kit were 57.5% and 100% respectively. When the NS1 Ag assay was combined with immunoglobulin IgM antibody capture ELISA, the sensitivity was significantly increased for dengue diagnosis. NS1 Ag positivity rate was found significantly higher in dengue fever (DF) cases than in fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). It was higher in primary rather than in secondary infections, in patients with a high viremia (>5 log/mL), and in patients infected with the dengue viral strain DENV-1. In asymptomatic individuals, the NS1 Ag capture sensitivity tends to be lower than that in symptomatic patients. Milder disease severity was observed independently in patients with ribonucleic acid (RNA) copy number >5 log10 complementary DNA (cDNA) equivalents/mL or in high level of NS1 antigen ratio or in DENV-1 infection.

The authors concluded that the overall sensitivity of the Platelia Dengue NS1 Ag detection kit (BioRad; Hercules, CA, USA) varied widely across the various forms of dengue infection or disease. Sensitivity was highest in patients sampled during the first three days after onset of fever, in patients with primary infection, DENV-1 infection, with high level of viremia and in DF rather than DHF/DSS. The semi-quantitative approach of the test, demonstrated that the NS1 antigen level was significantly correlated to the level of viremia and that the low level of NS1 antigen was associated with more severe disease. The study was published online on July 19, 2011, in the Public Library of Science Neglected Tropical Diseases.

Related Links:
Institute Pasteur
BioRad



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.